Effects of diabetes on small aortic aneurysms under surveillance according to a subgroup analysis from a randomized trial  by De Rango, Paola et al.
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analysis from a randomized trial
Paola De Rango, MD, PhD,a Piergiorgio Cao, MD, FRCS,b Enrico Cieri, MD, PhD,a
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Aneurysm Repair (CAESAR) investigators group, Perugia and Rome, Italy
Background: This study aims to investigate the impact of diabetes in the management of patients with small abdominal
aortic aneurysms (AAA).
Methods: Three-hundred sixty patients with small AAA (4.1-5.4 cm), enrolled in a randomized trial comparing early
endovascular repair versus surveillance and delayed repair (after achievement of >5.5 cm or growth >1 cm/yr), were
analyzed with standard survival methods to assess the relation between diabetes and risk of all-cause mortality,
complications, and aneurysm growth (on computed tomography as per trial protocol) at 36 months. Baseline covariates
were selected with partial likelihood stepwise method to investigate factors (demographic, morphologic, medications)
associated with risk of aneurysm growth during surveillance.
Results: Prevalence of diabetes was 13.6%. The hazard ratio (HR) for all-cause mortality at 36 months was higher in
diabetic compared with nondiabetic patients: (HR, 7.39; 95% confidence interval [CI], 1.55-35.13; P  .012). Baseline
aneurysm diameter was comparable between diabetic and nondiabetic patients enrolled in the surveillance arm and was
related to subsequent aneurysm growth in covariance analyses adjusted for diabetes (49.3 mm for nondiabetic; 50.2 mm
for diabetic). Cox analyses found diabetes as the strongest independent negative predictor of 63% lower probability of
aneurysm growth >5 mm during surveillance (HR, 0.37; 95% CI, 0.15-0.92; P  .003). Kaplan-Meier cumulative
probability of aneurysm growth >5 mm at 36 months was 40.8% in diabetics versus 85.1% in nondiabetics (HR, 0.32;
95% CI, 0.17-0.61).
Conclusions: Progression of small AAA seems to be more than 60% lower in patients with diabetes. This may help to
identify high-risk subgroups at higher likelihood of AAA enlargement, such as nondiabetics, for surveillance protocols in
patients with small AAA. (J Vasc Surg 2012;56:1555-63.)
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tAbdominal aortic aneurysm (AAA) is a common life-
threatening condition representing the tenth leading cause
of death for older men in the Western world, mainly
because of the high fatality associated with aneurysm rup-
ture.1 The universally used measure of rupture risk for AAA
is the diameter, and the only effective treatment is the
exclusion by intervention (either open surgery or endovas-
cular aortic aneurysm repair [EVAR]). In the last few years,
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http://dx.doi.org/10.1016/j.jvs.2012.05.078here has been an increasing interest in managing AAAwith
est medical therapy alone, avoiding invasive repair.2-4 It is
enerally assumed that therapies achieving slow AAA
rowth would result in a reduced aneurysm rupture risk.
evertheless, despite the enormous potential for disease-
odifying drugs, evidence is lacking, and there is currently
o accepted therapeutic agent or life-style modifier for the
anagement of AAA expansion. Diabetes is a common risk
actor that is known to predispose to cardiovascular disease
nd death.5,6 A number of studies suggested a potential and
pparently paradoxical negative association between diabe-
es or its medications and aortic aneurysm expansion.7-9
owever, the true link between AAA and diabetes remains
nsettled, and published work in this area is limited and
nconclusive.
The Comparison of surveillance versus Aortic En-
ografting for Small Aneurysm Repair (CAESAR) is a
ulticenter randomized trial designed to determine mor-
ality risks, complication rates, aneurysm enlargement rates,
nd health-related quality of life (QoL) after early EVAR
epair compared with periodic computed tomography
CT) and ultrasound surveillance in small aneurysms with
.1 cm to 5.4 cm diameter.10 CAESAR recently reported
hat 54-month mortality rates were similar in the two trial
rms: 14.5% in EVAR and 10.1% in the surveillance group
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December 20121556 De Rango et al(P  .6). Preliminary analysis of CAESAR results also
suggested a negative association between the presence of
diabetes and the requirement of repair in patients assigned
to surveillance for fast aneurysm expansion.10 Therefore,
we decided to provide further insight in this setting in a
secondary analysis of the CAESAR trial since the study
offered the opportunity to systematically follow and pro-
spectively analyze the natural evolution of small AAA under
surveillance in diabetic patients in the trial.
The aim of this study was to analyze whether diabetic
and nondiabetic patients with small AAAs share equal risks
of mortality, aneurysm growth, need for repair (in AAAs
assigned to surveillance), and complications.
METHODS
The methods of the CAESAR trial and the whole trial
investigators list have been previously published.10 Briefly,
CAESAR is a multicenter randomized clinical trial that
compares safety and efficacy of EVAR versus surveillance in
small AAAs. Patients with AAA of 4.1 cm to 5.4 cm were
randomly assigned by a web-based system (in a 1:1 ratio
with random blocks of four stratified by center) to receive
immediate EVAR or surveillance by ultrasound and CT
with repair allowed only after a defined threshold (diameter
5.5 cm, enlargement 1 cm/year and symptoms)
achievement. Full eligibility criteria have been previously
reported.10
The trial was performed according to the CONSORT
(CONsolidated Standards of Reporting Trials) State-
ment11 recommendations and registered at http://www.
clinicaltrials.gov withNCT Identifier: NCT00118573 (Study
ID Numbers ICMJE 384/03).
The study was approved by a central human rights
committee and the institutional review boards at each
participating center.
Patients were enrolled at 20 centers in Europe and
Western Asia. Participant-approved surgeons, selected ac-
cording to personal track record, performed all procedures.
For patients assigned to early EVAR, the transluminal
introduction of an aortic endograft system needed to be
performed as soon as possible.
Follow-up visits with clinical and ultrasound examina-
tions were scheduled at 1 month and every 6 months
thereafter. Plain X-ray and contrast-enhanced CT scan were
required yearly after EVAR.
Patients assigned to the surveillance arm were seen
every 6 months with clinical and ultrasonography studies
and annual CT scan. Surveillance was continued until the
patient died or repair was assigned or the trial ended. Repair
was allowed only when the aneurysm grew to 5.5 cm
diameter in size, rapidly increased in diameter (1 cm/
year), or became symptomatic. Patients under surveillance
who met one or more threshold criteria for repair were
treated as soon as possible. EVAR was performed if ana-
tomical suitability was maintained; alternatively, open sur-
gery was chosen.
The exposure variable for this secondary analysis was
the presence of diabetes mellitus at the time of enrollment. fiabetes was defined according to the Society for Vascular
urgery (SVS) definition and graded as 0 none; 1 adult
nset, controlled by diet or oral agents; 2  adult onset,
nsulin-controlled; and 3  juvenile onset.12
The primary end points for this analysis were all-cause
ortality and aneurysm growth rate5 mm (measured on
equential CT scans). Secondary end points included any
nd major adverse events (defined according to the Society
or Vascular Surgery and the American Association for
ascular Surgery [SVS/AAVS] reporting standards)12 in-
luding rupture, need for repair in patients assigned to
urveillance, and QoL.
Statistical analysis. We used similar statistical ap-
roaches as those for the CAESAR primary results.10 How-
ver, with respect to the original CAESAR study, here all
ata assessment was trimmed at 36 months. All analyses
ere by intention-to-treat. Continuous variables were re-
orted as frequency, mean, and standard deviation, or
edian and interquartile ranges when appropriate, mini-
um and maximum. Categorical variables were summa-
ized using contingency tables with frequency and percent-
ges. Comparisons between groups were performed using
tudent t-test for unpaired continuous data and 2 test,
ith Yates correction or the Fisher exact test when appro-
riate for categorical variables. Aneurysm growth in dia-
etic and nondiabetic patients under surveillance was as-
essed with linear regression and multiple regression
nalyses (covariance analyses). Diabetic and nondiabetic
atients were compared using standard survival methods.
urvival, aneurysm growth 5 mm, and need of repair for
AA under surveillance arm were assessed according to
aplan-Meier survival curves.
End point analyses adjusting for major baseline covari-
tes, including baseline diameter and diabetes, were con-
ucted using time-to-event statistical modeling. The asso-
iation between aneurysm growth 5 mm during
urveillance (measured on sequential CT scans required
uring follow-up as for trial protocol) and 18 major cova-
iates (age, gender, American Society of Anesthesiologists
ASA] score, smoking, hypertension, hyperlipidemia, car-
iac disease, pulmonary disease, renal failure, diabetes,
arotid stenosis, peripheral artery disease and aneurysm,
revious laparotomy, obesity, -blockers, statins, AAA di-
meter at baseline) were assessed by Cox regression analysis
ith forward stepwise selection using a P value of .15 for
emoval and of .10 for entering variables into the valid
odel. The significance probability of each variable was
stimated with partial likelihood-ratio test after checks of
roportional hazard assumption.
Data of QoL questionnaires were analyzed according
o the analysis of variance with repeated measures.
A value of P  .05 was considered statistically signifi-
ant.
Statistical analyses were performed using Bio-Medical
ata Package version, 2009 (Statistical Software Inc, Los
ngeles, Calif).
Role of the funding source. The trial was originallyunded with a grant by Cook Medical (William Cook
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Volume 56, Number 6 De Rango et al 1557Europe, Bjaeverskov, Denmark). In December 2006, the
sponsor withdrew. Enrollment and follow-up fees for pa-
tients included in the study after January 1, 2007 were not
paid by any sponsor, and the trial continued as a full
spontaneous research unfunded trial. The sponsor was
never involved in study design, data collection, data analy-
sis, data interpretation, or the writing of the first and the
present report. The corresponding author had full access to
all data and had final responsibility for the decision to
submit for publication.
RESULTS
Between August 2004 and December 2008, a total of
360 patients with mean aneurysm diameter 47.2 mm (stan-
dard deviation, 3.24) were randomly assigned to early
EVAR (n  182) or surveillance (n  178); 13.6% (n 
49/360) were diabetic. Diabetes (graded as 1 or 2 accord-
ing to SVS classification; there was no juvenile onset grade)
was similarly distributed between the two treatment arms:
15.9% (n  29/182) in early EVAR versus 11.2% (n 
Table I. Baseline characteristics in diabetic and nondiabet
Characteristics
Total
(n  360) %
Age (mean  SD) 68.9  6.8 —
EVAR 182 50.6
Surveillance 178 49.4
Males 345 95.8
Smoke 104 28.9
Coronary disease 141 39.2
Hypertension 271 75.3
Hyperlipidemia 225 62.5
Respiratory disease 22 6.1
Renal disease 29 8.1
AAA diameter (mean  SD) 47.2  3.2 —
Previous laparotomy 72 20.0
Unfit for open repair 14 3.9
Eurostar classification (D  E) 17 4.7
Obesity (BMI 31 kg/m2) 68 18.9
Aortic neck length (mean  SD) 27.9  12.5 —
Aortic neck diameter (mean  SD) 22.7  2.5 —
Iliac diameter (right) (mean  SD) 15.7  5.1 —
Iliac diameter (left) (mean  SD) 14.9  5.0 —
Neck thrombus 50% 8 2.2
Funnel shape neck 54 15.0
Symptomatic carotid stenosis 54 15.0
Peripheral artery disease 46 12.8
ASA 201 58.6
Statins 148 44.7
ACE inhibitors 158 46.9
Adrenergic blockers 20 6.1
Angiotensin blockers 42 13.2
Anticoagulants 19 5.9
Calcium channel blockers 92 28.7
Cardiac glycosides 8 2.5
Diuretics 89 27.4
Nitrates 29 9.2
Beta blockers 81 24.8
AAA, Abdominal aortic aneurysm; ACE, angiotensin-converting enzyme;
Comparison of surveillance versus Aortic Endografting for Small Aneurysm29/178) in surveillance arm (P  .25). There were no oignificant differences in age (mean, 68.9 years) and gender
4.2% females) between diabetic and nondiabetic patients
Table I). Prevalence of obesity (body mass index 31
g/m2) and use of diuretic drugs were higher in diabetics.
urthermore, diabetic patients shared similar baseline aor-
ic aneurysm diameters (47.5 mm vs 47.2 mm) with non-
iabetic patients but showed aortic neck diameter about 1
m larger (23.46 mm vs 22.54 mm; P .0183) and more
ften involved with thrombus (8.2% vs 1.3%; P  .0028).
Mean follow-up was 33.8 months (19.8 months) in
he diabetic group and 31.2months (16.6months) in the
ondiabetic group (P  .32).
Table II and Fig 1 provide details on survival rates by
resence of diabetes at 36 months. Only two deaths were
neurysm related. The hazard ratio (HR) for all-cause
ortality was higher in diabetic compared with nondiabetic
atients: HR 7.39 (95% confidence interval [CI], 1.55-
5.13; survival rates 88.0% vs 96.1%, respectively; P 
012).
During follow-up, 55 adverse events of any type
tients in the CAESAR study
Diabetic Nondiabetic
P(n  49) % (n  311) %
68.4  7.1 — 69.0  6.7 — .5851
29 59.2 153 49.2 .2518
20 40.8 158 50.8 .2518
47 95.9 298 95.8 .9744
17 34.7 87 28.0 .4266
16 32.7 125 40.2 .3967
42 85.7 229 73.9 .1002
33 67.3 192 61.7 .5517
5 10.2 17 5.5 .3340
7 14.3 22 7.1 .1494
47.5  3.6 — 47.2  3.2 — .4665
7 14.3 65 20.9 .3768
3 6.1 11 3.5 .6365
4 8.2 13 4.2 .7513
19 38.8 49 15.8 .0003
25.7  11.0 — 28.2  12.7 — .1820
23.5  2.4 — 22.5  2.5 — .0183
15.6  3.4 — 15.7  5.3 — .8708
15.1  4.0 — 14.9  5.1 — .8546
4 8.2 4 1.3 .0282
8 16.3 46 14.8 .9940
5 10.2 49 15.8 .4254
7 14.3 39 12.5 .9124
31 63.3 170 54.7 .4536
24 49.0 124 39.9 .6205
28 57.1 130 41.8 .0851
1 2.0 19 6.1 .3989
5 10.2 37 11.9 .9748
1 2.0 18 5.8 .4252
13 26.5 79 25.4 .9999
1 2.0 7 2.3 .9999
19 38.8 70 22.5 .0261
3 6.1 26 8.4 .8388
13 26.5 68 21.9 .6241
American Society of Anesthesiologists; BMI, body mass index; CAESAR,
r; EVAR, endovascular aortic aneurysm repair; SD, standard deviation.ic paccurred in 45 patients and were similarly distributed in
p
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probabilities of adverse events in diabetic versus nondi-
abetic patients at 36 months were 13.8% versus 11.8%
Table II. Late outcomes (36 months) in diabetic and non
Meier estimates
Primary end points
Survival
Diabetic
Nondiabetic
AAA growth 5 mm
Diabetic
Nondiabetic
AAA growth 5 mm in surveillance arm
Diabetic
Nondiabetic
Secondary end points
Any adverse events
Diabetic
Nondiabetic
Major adverse eventsa
Diabetic
Nondiabetic
Need for open repair in the surveillance arm (30 months)
Diabetic
Nondiabetic
AAA,Abdominal aortic aneurysm;CAESAR,Comparison of surveillance ve
hazard ratio.
aCrude numbers and Relative Risk.
Fig 1. Survival rates in diabetic and nondiabetic patients.(P  .77). Thirteen major adverse events occurred in 11 1atients according to the SVS standard definitions12 and
ere significantly more frequent in the diabetic group:
.2% versus 2.3%, relative risk, 3.63; 95% CI, 1.10 to
etic patients of the CAESAR study according to Kaplan-
ates % HR 95% CI P value
96.1 7.39 1.55-35.13 .012
88.0
9.1 0.43 0.24-0.77 .0047
41.4
40.8 0.32 0.17-0.61
85.1
1.14 0.46-2.83 .77
13.8
11.8
3.63 1.10-11.9 .048
8.16
2.25
0.61 0.34-1.08 .08
22.7
52.5
ortic Endografting for Small Aneurysm Repair;CI, confidence interval;HR,
onfidence interval;HR, hazard ratio; SE, standard error.diab
R
rsus A1.93; P  .048.
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Volume 56, Number 6 De Rango et al 1559In this substudy, analyses of aneurysm growth by dia-
betes were specifically focused on the surveillance arm. In
the surveillance group, larger mean aneurysm diameter at
baseline was related to aneurysm growth during follow-up
in both unadjusted and adjusted analyses (covariance anal-
yses) for the presence of diabetes (adjusted analyses: mean
diameter 49.3 mm in nondiabetic and 50.7 mm in diabet-
ics). Aneurysms’ diameter linear growth rates per each
follow-up year in nondiabetic and diabetic patients under
surveillance are shown in Table III. During the first year,
median growth rate was 0.044 mm for both diabetic and
nondiabetic groups; in the second follow-up year, there was
a trend for higher median growth rate in the nondiabetic
Table III. Yearly aneurysm growth rate in the surveillance
N Median 1st qua
1 year
Nondiabetes 127 0.0444 0.02
Diabetes 14 0.0444 0.02
2 year
Nondiabetes 78 0.0704 0.00
Diabetes 12 0.0085 0.02
3 year
Nondiabetes 26 0.0619 0.03
Diabetes 8 0.0505 0.01
Fig 2. Kaplan-Meier rates of aneurysm growth 5 mm
nondiabetic patients. CI, Confidence interval; HR, hazagroup (0.07 mm vs 0.008 mm). tWhen aneurysm enlargement data by diabetes were
nalyzed with Kaplan-Meier analyses using the established
utoff of 5 mm, there was evidence of a diabetic-specific
ifference in growth rates. Diabetic patients left under
urveillance had lower cumulative probability of aneurysm
rowth5 mm at 36 months, showing 68% risk reduction
elative to nondiabetic patients: HR, 0.32; 95% CI, 0.17 to
.61 (event rates 40.8% vs 85.1%, in diabetic and nondia-
etic) (Table II; Fig 2).
In the assessment of whether differences on aneurysm
rowth5mm during surveillance was affected by baseline
ovariates, Cox regression analyses with forward stepwise
election using a P value of .10 for entering variables into
in diabetic and nondiabetic patients
3rd quartile Minimum Maximum
0.0889 0.1176 0.2609
0.0948 0.0600 0.2857
0.1000 0.2647 0.2195
0.0577 0.0444 0.1200
0.1444 0.1493 0.2000
0.0592 0.0333 0.1000
6 months within the surveillance arm in diabetic and
io; SE, standard error.arm
rtile
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aneurysm growth 5 mm (HR, 0.37; 95% CI, 0.15-0.91;
P .0033). The presence of diabetes was indicative of 63%
lower risk of developing the event at 36 months.
According to primary CAESAR results, estimated
probability of receiving delayed repair in aneurysms under
surveillance was 59.7% at 36 months (and 84.5% at 54
months).10 Reasons for repair were due mainly to rapid
AAA expansion (aneurysm diameter achievement of 5.5
cm or rapid aneurysm growth 1 cm/year) and to devel-
opment of iliac aneurysm. In the present study, the need for
repair within the surveillance group at 30 months (curves
were trimmed after this time point due to standard error
10.0 thereafter for small numbers in this subgroup anal-
ysis of the surveillance arm alone) was lower in diabetic
patients compared with nondiabetic patients, even though
the difference did not reach statistical relevance: 22.7% vs
52.5%; HR, 0.61; 95% CI, 0.34-1.08; P  .08 (Fig 3).
Baseline total QoL score (69.8 vs 74.9) and Mental
Health perception scores (68.0 vs 72.4) were not statisti-
cally different, but mean Physical Health perception score
was significantly lower in diabetics versus nondiabetics
(66.6 vs 73.2; P .019). There were no significant changes
in QoL score (with respect to baseline) in nondiabetic
patients after 6 and 12 months and for each randomization
arm. At 6 months, diabetic patients showed transient im-
provement of total score (5.8 difference; P  .029) and
Fig 3. Kaplan-Meier rates of need of repair within the
Confidence interval; HR, hazard ratio; SE, standard erroMental Health score (6.1 difference; P  .0397) in the mVAR arm and deterioration of total score (8.2 differ-
nce; P  .002) and Mental Health score (10.3 differ-
nce; P  .0006) in the surveillance arm. At the last
valuation (1 year or more after randomization), diabetic
atients showed a significant decrease in the total QoL
core (13.5 difference from baseline; P  .0001), in the
hysical Health perception (15.2 difference; P .0001),
nd in the Mental Health perception (10.7 difference;
 .0001) scores. There were similar score changes in
VAR and surveillance arms.
ISCUSSION
These CAESAR results demonstrated that diabetic pa-
ients with small AAA had an approximately seven-fold
ncrease in all-cause mortality risk at 36 months (HR 7.39;
urvival rates 88.0% vs 96.1%) when compared with nondi-
betic patients. The risk of major adverse events was also
ore than three-fold higher (8.2% vs 2.3%; P  .048).
owever, patients with diabetes left under surveillance had
statistically significant lower risk, relative to nondiabetics,
f experiencing an increase of 5 mm or more in AAA
iameter at 36 months despite of a 1 mm larger aortic
eck diameter at baseline. The presence of diabetes, ad-
usted for other covariates, was indicative of 63% lower risk
f developing the event (HR, 0.37; 95%CI, 0.15-0.91; P
0033). Furthermore, the risk of requiring repair for rapid
neurysm expansion at 30 months after surveillance assign-
eillance arm in diabetic and nondiabetic patients. CI,survent was decreased from 22.7% to 52.5% in diabetic pa-
s
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(P .08) on Kaplan-Meier analysis. However, these results
from a randomized controlled trial on small AAAs should
be interpreted with caution because they are based on
nonpowered calculations and nonrandomized assignment
to compare diabetic and nondiabetic patients, and small
numbers.
CAESAR findings suggest that the presence of diabetes
might be an additional factor to select the best strategy to
apply in individual small AAAs. It has been shown that for
patients with small AAA under surveillance, the risk of
death, aneurysm-related death, and aneurysm rupture are
very low (less than 1% per year) and, therefore, surveillance
has been largely recognized as the best strategy for most
patients.10,13-15 However, there are subgroups of “rapid
growing” small AAAs in which risks are significantly higher.
According to the main results of CAESAR trial, within 36
months, three out of five small aneurysms under surveil-
lance may grow to require repair and one of every six may
lose feasibility for EVAR.10 Lack of diabetes or of diabetes-
drug exposure might be a relevant indicator of more than
twice the increased risk of small AAA growth, an issue that,
however, has yet to be fully explored and defined. There-
fore, a preferred surveillance strategy should be applied to
the majority of small AAAs but needs to be careful, contin-
uous, and active, while an “early EVAR” strategy might be
justified in some small AAAs at unexpected higher risk of
rapid growth, such as in some nondiabetic settings. The
protective effect of diabetes or diabetes drug exposure in
decreasing AAA growth rate may suggest intensifying
screening protocols for AAA detection and surveillance,
particularly in nondiabetic populations that, paradoxically,
are those with lower cardiovascular risks. On the other side,
given the slow aneurysm growth rates in diabetics, the
similar age (68.4 years vs 69 years) and comparable aneu-
rysm diameter (4.7 cm) detected at baseline between dia-
betic and nondiabetic patients in CAESAR, might also
suggest an early development of AAA at younger age or
faster earlier aneurysm growth in the diabetic group, re-
quiring implementation of AAA screening strategies at
younger ages in the diabetic population. These hypotheses
could not be answered by CAESAR data and need to be
validated by larger prevalence studies on diabetic patients
followed at younger age.
CAESAR confirmed that exposure to diabetes or hypo-
glycemic medications was the single association with base-
line characteristics to maintain relevance through Cox mul-
tivariate analysis on the risk of5 mm AAA growth during
surveillance assessed on CT scan as per trial protocol. This
is supported by several studies that demonstrated a protec-
tive role of diabetes in AAA expansion or develop-
ment.7-9,16,17 Similarly to CAESAR and more than 10 years
earlier, Kang et al, in a prevalence study, demonstrated with
multivariate analysis that the presence of diabetes decreased
the risk of AAA, higher in the presence of carotid stenosis:
AAA4 cm was detected in 10.2% of nondiabetic patients
with 50% carotid stenosis versus 2.8% of the correspond-
ing diabetic population.16 Lederle et al, in a large cohort study of veterans, detected 1568 AAA from 114,419 sub-
ects aged 50 to 79 years without history of AAA who
nderwent successful ultrasound screening. Diabetes mel-
itus (odds ratio [OR], 0.52; 95%CI, 0.45-0.61) was one of
he main negative associations with AAA prevalence as well
s female gender, and black race.8 Nevertheless, the exact
echanism linking diabetes and AAA growth rates is unde-
ermined, and no single subclass of diabetic therapeutic
gents (including insulin) has been shown to show greater
ffect than others,2,4 making it likely that diabetes has a
rotective role rather than the actions of its therapeutic
gents. Demonstrating independent effects of single ther-
peutic agents through multivariate analysis was not possi-
le in our study due to the small numbers and the multiple
rug approach in many of these patients. In addition, the
ost frequent use of diuretic drugs in CAESAR diabetic
atients might have influenced the better outcome on AAA
rowth, since studies have also demonstrated a significant
ssociation of diuretics with slow growth rates of AAA
eparate from their effect of blood pressure.18
A direct protective effect of diabetes more than of
iabetes drugs could not be excluded by CAESAR study.
revious human and animal studies have identified distin-
uished changes in the aortic wall and characteristics of the
ural thrombus within it in diabetic settings.7,19-23 In the
AESAR study, there was a significant higher thrombus
eposition at the neck level in diabetic patients (8.2% vs
.2%; P .02). This might potentially be a protective factor
xplaining higher resistance to expansion of the aneurysm
n diabetic patients since the clot is often more stable due to
brinolytic system alterations induced by hyperglycemia as
uggested by other studies.19-20 Recently, Dunn et al found
hat the fibrin clot in type 2 diabetics is altered, being
enser, less porous, and more resistant to fibrinolysis.19
ther studies also suggested lesser release of components
mplicated in aneurysm growth as matrix metalloprotein-
ses (MMP-9) and elevated levels of plasminogen activator
nhibitor-1 suppressing fibrinolysis, in the intraluminal
hrombus of patients with hyperinsulinemia.7,20 These fac-
ors could aid aneurysmal wall stabilization and reduce clot
egradation and renewal so that the more degradation-
esistant clot in diabetes may slow the rate of expansion
sually favored by matrix metalloproteinases and fibrino-
ytic mediators.
In addition, diabetes seems characterized by increased
all stiffness and thickness that probably does not allow the
ortic wall to expand as fast as in patients without diabe-
es.7,16,21-23 Hyperglycemia with subsequent elevated for-
ation of advanced glycation end products can promote
ovalent crosslinks between proteins, including elastin and
ollagen in the vessel wall and smooth cell proliferation that
ay result in a stiffened aortic aneurysm wall, which is
esistant to proteolysis. Increased synthesis of collagen and
educed degradation of the matrix resulting in enhanced
atrix volume have been demonstrated associated with
iabetes.22 However, there was no analysis of aortic wall
tiffness in the CAESAR trial to support this data.
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a major risk factor for cardiovascular morbidity and mortal-
ity.5,6 In CAESAR, survival rates were significantly lower,
and major adverse event rates significantly more frequent in
diabetic population with small AAA relative to those with-
out diabetes. Diabetes also influenced worse health percep-
tion and decreasing QoL. It has been shown that individ-
uals with diabetes are at two- to three-fold increased risk for
cardiovascular disease and mortality.5 This may be related
to a worse cardiovascular risk factor profile control in
individuals with diabetes even though the exact mechanism
linking diabetes and adverse event rate remains un-
known.5,24-25 Accordingly, in the CAESAR population,
excess body mass index was prevalent in the diabetic group,
and this could have affected the worse mortality and ad-
verse event outcome. The higher cardiovascular mortality,
the increased major adverse event rates associated with
repair, and the slower aneurysm expansion suggest the
superiority of a conservative approach in most diabetic
patients with 4 cm to 5 cm AAA.
Limitations. Despite the advantage of a group of pa-
tients enrolled in a randomized controlled trial and pro-
spectively followed, the number of diabetic patients within
the CAESAR study was limited, and the study was not
specifically powered to compare diabetics and nondiabetics.
Compliance was another issue as in any therapeutic study,
as well as the lack of metabolic control-specific information
as for HbA1c. Independent effects of single therapeutic
agents (as well as insulin) were not possible through Cox
multivariable analysis due to the polypharmaceutical ap-
proach in many of these patients and the small events-to-
numbers for model power/significance.
CONCLUSIONS
Diabetes is a major risk factor for cardiovascular out-
come in patients with small AAAs, resulting in increased
mortality and morbidity and poorer QoL. Nevertheless,
diabetes exposure is independently associated with altered
and more than 60% decreased AAA growth risk relative to
nondiabetes. Although the protective role of diabetes on
AAA enlargement remains unclear and needs further con-
firmation, this finding may be helpful in selecting strategies
for management of small AAA. The possible link between
diabetes and slow AAA growth may suggest implementing
screening protocols for small AAA also in nondiabetic
populations who are usually considered at lower cardiovas-
cular risk. Further studies could help selecting subgroups of
diabetic patients, if any, at higher risk of AAA expansion
and lower cardiovascular risk that could benefit from an
early EVAR. In the meantime, for most diabetic patients
with small 4 cm to 5 cmAAA, the slower aneurysm enlarge-
ment and the higher cardiovascular mortality, suggest a
surveillance strategy without AAA repair.
The authors thank Benito Chinea and Fabio Bravi, Ibis
Informatica, Milan, Italy, for statistical analysis assistance
and Francesca Zannetti and Eileen Mahoney for editing
support.UTHOR CONTRIBUTIONS
onception and design: PDR, EC, FV
nalysis and interpretation: PDR, GS, EC, FV
ata collection: EC, GP, GS, FV
riting the article: PDR, EC
ritical revision of the article: PDR, PC, GP, FV
inal approval of the article: PDR, PC, EC, GP, GS, FV
tatistical analysis: PDR, EC
btained funding: PC
verall responsibility: PDR, PC, FV
EFERENCES
1. Silverberg E, Boring CC, Squires TS. Cancer statistics. CA Cancer
J Clin 1990;1990:9-26.
2. Thompson A, Cooper JA, Fabricius M, Humphries SE, Ashton HA,
Hafez H. An analysis of drug modulation of abdominal aortic aneurysm
growth through 25 years of surveillance. J Vasc Surg 2010;52:55-61.
3. Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT, UK
Small Aneurysm Trial Participants, for the UK Small Aneurysm Trial
Participants. Abdominal aortic aneurysm expansion: risk factors and
time intervals for surveillance. Circulation 2004;110:16-21.
4. Golledge J, Powell JT. Medical management of abdominal aortic aneu-
rysm. Eur J Vasc Endovasc Surg 2007;34:267-73.
5. Preis SR, Hwang SJ, Coady S, Pencina MJ, D’Agostino RB Sr, Savage
PJ, et al. Trends in all-cause and cardiovascular disease mortality among
women and men with and without diabetes mellitus in the Framingham
Heart Study, 1950 to 2005. Circulation 2009;119:1728-35.
6. Chaikof EL, Brewster DC, Dalman RL, Makaroun MS, Illig KA, Sicard
GA, et al. The care of patients with an abdominal aortic aneurysm: the
Society for Vascular Surgery practice guidelines. J Vasc Surg 2009;50(4
Suppl):S2-49.
7. Shantikumar S, Ajjan R, Porter KE, Scott DJ. Diabetes and the abdom-
inal aortic aneurysm. Eur J Vasc Endovasc Surg 2010;39:200-7.
8. Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun
MS, et al. The aneurysm detection and management study screening
program: validation cohort and final results. Aneurysm detection and
management. Veterans Affairs cooperative study investigators. Arch
Intern Med 2000;160:1425-30.
9. Bergqvist D. Pharmacological interventions to attenuate the expansion
of abdominal aortic aneurysm (AAA) - a systematic review. Eur J Vasc
Endovasc Surg 2011;41:663-7.
0. Cao P, De Rango P, Verzini F, Parlani G, Romano L, Cieri E, et al.
Comparison of surveillance versus aortic endografting for small aneu-
rysm repair (CAESAR): results from a randomised trial. Eur J Vasc
Endovasc Surg 2011;41:13-25.
1. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT
2010 statement: updated guidelines for reporting parallel group ran-
domized trials. BMJ 2010;2010:c332.
2. Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK,
Bernhard VM, et al. Ad Hoc Committee for Standardized Reporting
Practices in Vascular Surgery of the Society for Vascular Surgery/
American Association for Vascular Surgery. Reporting standards
for endovascular aortic aneurysm repair. J Vasc Surg 2002;35:
1048-60.
3. Ouriel K, Clair DG, Kent KC, Zarins CK; Positive Impact of Endovas-
cular Options for treating Aneurysms Early (PIVOTAL) Investigators.
Endovascular repair compared with surveillance for patients with small
abdominal aortic aneurysms. J Vasc Surg 2010;51:1081-7.
4. Powell JT, Brown LC, Forbes JF, Fowkes FG, Greenhalgh RM, Ruck-
ley CV, et al. Final 12-year follow-up of surgery versus surveillance in
the UK small aneurysm trial. Br J Surg 2007;94:702-8.
5. Lederle FA, Kane RL, MacDonald R, Wilt TJ. Systematic review: repair
of unruptured abdominal aortic aneurysm. Ann Intern Med 2007;146:
735-41.
6. Kang SS, Littooy FN, Gupta SR, Johnson GR, Fisher SG, Cote WL, et
al. Higher prevalence of abdominal aortic aneurysms in patients with
carotid stenosis but without diabetes. Surgery 1999;126:687-91.
22
2
2
JOURNAL OF VASCULAR SURGERY
Volume 56, Number 6 De Rango et al 156317. Ferguson CD, Clancy P, Bourke B, Walker PJ, Dear A, Buckenham T,
et al. Association of statin prescription with small abdominal aortic
aneurysm progression. Am Heart J 2010;159:307-13.
18. Cassis LA, Helton MJ, Howatt DA, King VL, Daugherty A. Aldoste-
rone does not mediate angiotensin II-induced atherosclerosis and ab-
dominal aortic aneurysms. Br J Pharmacol 2005;144:443-8.
19. Dunn EJ, Ariëns RA, Grant PJ. The influence of type 2 diabetes on
fibrin structure and function. Diabetologia 2005;48:1198-206.
20. Houard X, Rouzet F, Touat Z, PhilippeM, DominguezM, Fontaine V,
et al. Topology of the fibrinolytic system within the mural thrombus of
human abdominal aortic aneurysms. J Pathol 2007;212:20-8.
21. Festa A, D’Agostino R Jr, Mykkänen L, Tracy RP, Zaccaro DJ, Hales
CN, et al. Relative contribution of insulin and its precursors to fibrin-
ogen and PAI-1 in a large population with different states of glucose
tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arte-
rioscler Thromb Vasc Biol 1999;19:562-8. S2. Golledge J, Karan M, Moran CS, Muller J, Clancy P, Dear AE, et al.
Reduced expansion rate of abdominal aortic aneurysms in patients with
diabetes may be related to aberrant monocyte-matrix interactions. Eur
Heart J 2008;29:665-72.
3. Astrand H, Rydén-Ahlgren A, Sundkvist G, Sandgren T, Länne T.
Reduced aortic wall stress in diabetes mellitus. Eur J Vasc Endovasc
Surg 2007;33:592-8.
4. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for
vascular disease among adults with previously diagnosed diabetes.
JAMA 2004;291:335-42.
5. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes
mellitus: blood pressure goals, choice of agents, and setting priorities in
diabetes care. Ann Intern Med 2003;138:593-602.ubmitted Feb 28, 2012; accepted May 18, 2012.
